AEON Biopharma, Inc.
AEONAMEXHealthcare● Active
$0.74
+$0.02(+2.08%)
Market Cap$8715411
P/E Ratio—
52W High$1.45
52W Low$0.625
AEON Biopharma, Inc. (AEON) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AEON · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$0.44
Est. -$0.44 · +0.0%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
✓ 1-Quarter EPS Beat Streak
AEON reports quarterly as a AMEX-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.19
Rev. $0.35B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.19
Rev. Est.$0.35B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.33 | — | — | — | — | — |
| — Q2 FY2026 | May 14, 2026 | -$0.44 | -$0.44 | +0.0% | — | — | — |
| ▼ Q1 FY2026 | Mar 30, 2026 | -$0.20 | -$3.72 | -1714.6% | — | — | — |
| ▲ Q4 FY2025 | Nov 14, 2025 | -$0.43 | -$0.39 | +9.3% | — | — | — |
| — Q3 FY2025 | Aug 12, 2025 | — | -$0.60 | — | — | — | — |
| ▲ Q2 FY2025 | May 14, 2025 | -$13.67 | -$0.09 | +99.3% | — | — | — |
| ▲ Q1 FY2025 | Mar 24, 2025 | -$12.95 | $3.75 | +129.0% | — | — | — |
| — Q4 FY2024 | Nov 13, 2024 | -$11.51 | -$11.51 | +0.0% | — | — | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.33
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026
EPS Actual
-$0.44
EPS Est.
-$0.44
EPS Surpr.
+0.0%
Revenue
—
Q1 FY2026
Mar 30, 2026Miss
EPS Actual
-$3.72
EPS Est.
-$0.20
EPS Surpr.
-1714.6%
Revenue
—
Q4 FY2025
Nov 14, 2025Beat
EPS Actual
-$0.39
EPS Est.
-$0.43
EPS Surpr.
+9.3%
Revenue
—
Q3 FY2025
Aug 12, 2025
EPS Actual
-$0.60
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 14, 2025Beat
EPS Actual
-$0.09
EPS Est.
-$13.67
EPS Surpr.
+99.3%
Revenue
—
Q1 FY2025
Mar 24, 2025Beat
EPS Actual
$3.75
EPS Est.
-$12.95
EPS Surpr.
+129.0%
Revenue
—
Q4 FY2024
Nov 13, 2024
EPS Actual
-$11.51
EPS Est.
-$11.51
EPS Surpr.
+0.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.17 | $-0.17 | $-0.17 | 1 |
| Q3 FY2026 | $-0.27 | $-0.27 | $-0.27 | 1 |
| Q2 FY2026 | $-0.33 | $-0.33 | $-0.33 | 1 |
| Q1 FY2026 | $-0.44 | $-0.44 | $-0.44 | 1 |
| Q4 FY2025 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Q3 FY2025 | $-0.43 | $-0.43 | $-0.43 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 14, 2026 | +0.0% | $0.82 | $0.80 | -2.32% |
| ▼ Q1 FY2026 | Mar 30, 2026 | -1714.6% | $1.16 | $0.99 | -14.70% |
| ▲ Q4 FY2025 | Nov 14, 2025 | +9.3% | $0.94 | $0.90 | -3.77% |
| — Q3 FY2025 | Aug 12, 2025 | — | $0.66 | $0.69 | +4.87% |
| ▲ Q2 FY2025 | May 14, 2025 | +99.3% | $0.50 | $0.50 | -0.80% |
| ▲ Q1 FY2025 | Mar 24, 2025 | +129.0% | $0.67 | $0.72 | +8.06% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +0.0% | $54.07 | $49.69 | -8.10% |
| ▲ Q3 FY2024 | Aug 12, 2024 | +15.8% | $74.88 | $71.99 | -3.86% |
Q2 FY2026-2.32%
Report Date
May 14, 2026
EPS Beat/Miss
+0.0%
Price Before
$0.82
Price After
$0.80
Q1 FY2026-14.70%
Report Date
Mar 30, 2026
EPS Beat/Miss
-1714.6%
Price Before
$1.16
Price After
$0.99
Q4 FY2025-3.77%
Report Date
Nov 14, 2025
EPS Beat/Miss
+9.3%
Price Before
$0.94
Price After
$0.90
Q3 FY2025+4.87%
Report Date
Aug 12, 2025
EPS Beat/Miss
—
Price Before
$0.66
Price After
$0.69
Q2 FY2025-0.80%
Report Date
May 14, 2025
EPS Beat/Miss
+99.3%
Price Before
$0.50
Price After
$0.50
Q1 FY2025+8.06%
Report Date
Mar 24, 2025
EPS Beat/Miss
+129.0%
Price Before
$0.67
Price After
$0.72
Q4 FY2024-8.10%
Report Date
Nov 13, 2024
EPS Beat/Miss
+0.0%
Price Before
$54.07
Price After
$49.69
Q3 FY2024-3.86%
Report Date
Aug 12, 2024
EPS Beat/Miss
+15.8%
Price Before
$74.88
Price After
$71.99
Avg Beat Reaction-1.80%
Avg Miss Reaction-14.70%
Beat Rate6 / 8 quarters
Largest Move-14.70% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AEON ends December
AEON Biopharma, Inc. (AEON) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-0.44 (in line with the analyst consensus of $-0.44). The next AEON earnings date is expected around September 1, 2026.
Each quarter, investors track AEON earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AEON revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AEON's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AEON earnings · 4 questionsAEON Biopharma, Inc.'s next earnings report is expected around September 1, 2026. AEON typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AEON historically reports after market close (AMC).
AEON earnings datewhen is AEON earningsAEON next earnings datewhen does AEON report earningsAEON earnings calendar
▸ Source: FMP · AEON Biopharma, Inc. SEC filings · US GAAP · AEON Biopharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026